 |
|
Ethical Issues in the Reporting of Clinical Trials
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: We hope the revised CONSORT statement will contribute to further improvements in the reporting of unbiased results of randomized controlled trials (RCTs).1 However, the CONSORT statement continues to neglect one of the most important aspects of the design and conduct of RCTs: the choice of an adequate control group.2 A randomized trial can adhere to all of the CONSORT statement's recommendations and yet still be biased if the investigators have selected an inferior comparator intervention for their control group.3-4 For example, it was recently shown that studies sponsored by pharmaceutical companies were judged superior or equal to studies funded by public resources for the most of the quality items incorporated in the CONSORT statement.4-5 However, these studies were potentially biased by more frequent use of a placebo/no therapy control group as a comparator. One way to ensure that an adequate control group is used lies in the . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials
David Moher, Kenneth F. Schulz, Douglas Altman, and for the CONSORT Group
JAMA. 2001;285(15):1987-1991.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Improving the Methodologic and Ethical Validity of Best Supportive Care Studies in Oncology: Lessons From a Systematic Review
Cherny et al.
JCO 2009;27:5476-5486.
ABSTRACT
| FULL TEXT
Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals.
Kober et al.
JNCI J Natl Cancer Inst 2006;98:620-625.
ABSTRACT
| FULL TEXT
|
